{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:05:38Z","timestamp":1789067138795,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005049","name":"Science and Engineering Research Council of A*STAR","doi-asserted-by":"publisher","award":["ICES\/13-422A02"],"award-info":[{"award-number":["ICES\/13-422A02"]}],"id":[{"id":"10.13039\/501100005049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.xphs.2016.02.007","type":"journal-article","created":{"date-parts":[[2016,3,26]],"date-time":"2016-03-26T14:47:38Z","timestamp":1459003658000},"page":"1501-1512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy"],"prefix":"10.1016","volume":"105","author":[{"given":"Sie Huey","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Kiong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald B.H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhin.2009.10.024","article-title":"Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit","volume":"74","author":"Kohlenberg","year":"2010","journal-title":"J\u00a0Hosp Infect"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3949\/ccjm.80a.12182","article-title":"Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients","volume":"80","author":"Perez","year":"2013","journal-title":"Cleve Clin J Med"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.007_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/AAC.01020-10","article-title":"Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan","volume":"55","author":"Marchaim","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","article-title":"Evaluation of colistin as an agent against multi-resistant in gram-negative bacteria","volume":"25","author":"Li","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.007_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajic.2013.09.003","article-title":"Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes","volume":"42","author":"Ozgur","year":"2014","journal-title":"Am J Infect Control"},{"issue":"10","key":"10.1016\/j.xphs.2016.02.007_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10096-014-2124-9","article-title":"Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review","volume":"33","author":"Poulikakos","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.007_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1517\/13543784.17.7.973","article-title":"Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives","volume":"17","author":"Falagas","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.xphs.2016.02.007_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1586\/eri.12.78","article-title":"Colistin: an update on the antibiotic of the 21st century","volume":"10","author":"Biswas","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.007_bib9","first-page":"621","article-title":"The in-vitro activity of colistin in gram-negative bacteria","volume":"47","author":"Tan","year":"2006","journal-title":"Singapore Med J"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.007_bib10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1128\/JCM.02301-09","article-title":"Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study","volume":"48","author":"Zarkotou","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib11","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkl562","article-title":"Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster","volume":"59","author":"Antoniadou","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ppul.10166","article-title":"Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center","volume":"34","author":"Denton","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/AAC.00762-09","article-title":"Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea","volume":"54","author":"Suh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2016.02.007_bib14","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/BF02561666","article-title":"Combination therapy as a tool to prevent emergence of bacterial resistance","volume":"27","author":"Mouton","year":"1999","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.007_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpb.2012.09.002","article-title":"Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in\u00a0vitro evaluation","volume":"83","author":"Lee","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2016.02.007_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejps.2015.01.005","article-title":"A\u00a0novel inhaled multi-pronged attack against respiratory bacteria","volume":"70","author":"Lee","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2016.02.007_bib17","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/653050","article-title":"Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia","volume":"51","author":"Chastre","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.007_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0149-2918(96)80005-1","article-title":"Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs","volume":"18","author":"Elmore","year":"1996","journal-title":"Clin Ther"},{"key":"10.1016\/j.xphs.2016.02.007_bib19","series-title":"Respiratory Disease in Children: Diagnosis and Management","first-page":"721","year":"1994"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1378\/chest.119.4.1123","article-title":"Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis","volume":"119","author":"Coates","year":"2001","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.007_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/17425240903110710","article-title":"Delivery of antibiotics to the respiratory tract: an update","volume":"6","author":"Traini","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0939-6411(02)00043-7","article-title":"Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle","volume":"54","author":"de Boer","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0939-6411(02)00044-9","article-title":"Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients","volume":"54","author":"Le Brun","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.007_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2010.10.012","article-title":"Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy","volume":"403","author":"Lee","year":"2011","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.007_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/17425247.2011.588206","article-title":"The nano spray dryer B-90","volume":"8","author":"Heng","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jps.23874","article-title":"Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy","volume":"103","author":"Lee","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2016.02.007_bib28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.xphs.2016.02.007_bib29","series-title":"European Pharmacopoeia","year":"2010"},{"issue":"S2","key":"10.1016\/j.xphs.2016.02.007_bib30","first-page":"ii25","article-title":"Antibiotic dosing in critical illness","volume":"66","author":"McKenzie","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1128\/AEM.18.4.692-693.1969","article-title":"Stability of rifampin in dimethylsulfoxide","volume":"18","author":"Karlson","year":"1969","journal-title":"Appl Microbiol"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib32","first-page":"7","article-title":"Tigecycline: its position between other antibiotics, features, clinical usage","volume":"15","author":"Benes","year":"2009","journal-title":"Klin Mikrobiol Infekc Lek"},{"key":"10.1016\/j.xphs.2016.02.007_bib33","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2015. Available at: http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed September 1, 2015."},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/AAC.47.4.1364-1370.2003","article-title":"Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography","volume":"47","author":"Li","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.007_bib35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s11095-008-9560-0","article-title":"What is a suitable dissolution method for drug nanoparticles?","volume":"25","author":"Heng","year":"2008","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.007_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijpharm.2011.10.028","article-title":"Determination of moisture content in relation to thermal behaviour and plasticization of Eudragit RLPO","volume":"422","author":"Pirayavaraporn","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2016.02.007_bib37","first-page":"135","article-title":"Physiological investigation of resin-treated fabrics from Tencel\u00ae and other cellulosic fibres","volume":"87","author":"Varga","year":"2009","journal-title":"Lenzinger Berichte"},{"key":"10.1016\/j.xphs.2016.02.007_bib38","series-title":"British Pharmacopoeia Appendix XII C","year":"2009"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib39","first-page":"1","article-title":"A\u00a0simple HPLC method for the separation of colistimethate sodium and colistin sulphate","volume":"2","author":"Bai","year":"2011","journal-title":"J\u00a0Chromatograph Separat Techniq"},{"key":"10.1016\/j.xphs.2016.02.007_bib40","series-title":"ICH harmonised tripartite guideline, validation of analytical procedures: text and methodology Q2(R1)","first-page":"1","year":"2005"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.007_bib41","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.49.9.3903-3909.2005","article-title":"Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize\u00a0the test method","volume":"49","author":"Bradford","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2016.02.007_bib42","first-page":"254","article-title":"Rapid spectrophotometric method for determination of hexamethylenetetramine (urotropine) in foot care products","volume":"48","author":"Tachev","year":"2013","journal-title":"J\u00a0Chem Technol Metall"},{"key":"10.1016\/j.xphs.2016.02.007_bib43","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dkn425","article-title":"In\u00a0vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae","volume":"62","author":"Poudyal","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2016.02.007_bib44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkl512","article-title":"In\u00a0vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates","volume":"59","author":"Owen","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/AAC.29.1.179","article-title":"In\u00a0vitro activity of antibiotics alone and in combination against actinobacillus actinomycetemcomitans","volume":"29","author":"Yogev","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2016.02.007_bib46","series-title":"Antibiotics in Laboratory Medicine","first-page":"365","article-title":"Antimicrobial combinations","author":"Pillai","year":"2005"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib47","first-page":"44","article-title":"Combination drugs: innovation in pharmacotherapy","volume":"27","author":"Wertheimer","year":"2002","journal-title":"Pharm Ther"},{"issue":"7136","key":"10.1016\/j.xphs.2016.02.007_bib48","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nature05685","article-title":"Antibiotic interactions that select against resistance","volume":"446","author":"Chait","year":"2007","journal-title":"Nature"},{"issue":"Suppl 3","key":"10.1016\/j.xphs.2016.02.007_bib49","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.007_bib50","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01499-05","article-title":"Functional, biophysical, and structural bases for antibacterial activity of tigecycline","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib51","first-page":"274","article-title":"Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii","volume":"53","author":"Motaouakkil","year":"2006","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.xphs.2016.02.007_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/1471-2334-10-287","article-title":"Tigecycline use in serious nosocomial infections: a drug use evaluation","volume":"10","author":"Bassetti","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.xphs.2016.02.007_bib53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nrd1857","article-title":"Tigecycline","volume":"4","author":"Wenzel","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.xphs.2016.02.007_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/38.3.523","article-title":"Intravenous meropenem versus imipenem\/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group","volume":"38","author":"Colardyn","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.007_bib55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00006454-199907000-00012","article-title":"Uses of rifampin for infections other than tuberculosis","volume":"18","author":"Loeffler","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.007_bib56","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/106002809402800910","article-title":"Meropenem: a new carbapenem antimicrobial","volume":"28","author":"Pryka","year":"1994","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.007_bib57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/eri.11.28","article-title":"Status report on carbapenemases: challenges and prospects","volume":"9","author":"Patel","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.007_bib58","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkr056","article-title":"Comparative activity of carbapenem testing: the COMPACT study","volume":"66","author":"Nordmann","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.007_bib59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"14","key":"10.1016\/j.xphs.2016.02.007_bib60","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1517\/14656566.2011.599320","article-title":"Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens","volume":"12","author":"Jean","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib61","first-page":"273","article-title":"Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens","volume":"58","author":"Poulakou","year":"2009","journal-title":"J\u00a0Infect"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.007_bib62","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/07373930701536718","article-title":"Crystallization of amorphous components in spray-dried powders","volume":"25","author":"Chiou","year":"2007","journal-title":"Dry Technol"},{"issue":"11","key":"10.1016\/j.xphs.2016.02.007_bib63","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1021\/nn203115u","article-title":"Compression and aggregation-resistant particles of crumpled soft sheets","volume":"5","author":"Luo","year":"2011","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.xphs.2016.02.007_bib64","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1167\/iovs.15-17077","article-title":"Pharmacokinetics of meropenem for use in bacterial keratitis","volume":"56","author":"Sueke","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.007_bib65","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11095-007-9497-8","article-title":"Anomalous particle size shift during post-milling storage","volume":"25","author":"Ng","year":"2008","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/10837459908984232","article-title":"The effect of temperature on water vapor sorption by some amorphous pharmaceutical sugars","volume":"4","author":"Hancock","year":"1999","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2016.02.007_bib67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0378-5173(95)00083-U","article-title":"The use of gravimetric studies to assess the degree of crystallinity of predominantly crystalline powders","volume":"123","author":"Buckton","year":"1995","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2016.02.007_bib68","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1002\/jps.24160","article-title":"Dynamic vapor sorption as a tool for characterization and quantification of amorphous content in predominantly crystalline materials","volume":"103","author":"Sheokand","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.02.007_bib69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.powtec.2012.04.056","article-title":"Assessing the combinatorial influence of climate, formulation and device on powder aerosolization using the Taguchi experimental design","volume":"226","author":"Heng","year":"2012","journal-title":"Powder Technol"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.007_bib70","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijpharm.2013.05.006","article-title":"Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization","volume":"452","author":"Heng","year":"2013","journal-title":"Int J Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2016.02.007_bib71","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","article-title":"Use of solid corrugated particles to enhance powder aerosol performance","volume":"18","author":"Chew","year":"2001","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11095-004-9020-4","article-title":"How much particle surface corrugation is sufficient to improve aerosol performance of powders?","volume":"22","author":"Chew","year":"2005","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.007_bib73","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.007_bib74","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.007_bib75","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/jac\/dki153","article-title":"Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B","volume":"55","author":"Landman","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.007_bib76","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/338786","article-title":"Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-pectrum beta-lactamase in Pseudomonas aeruginosa in Thailand","volume":"34","author":"Girlich","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.007_bib77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/10766290152773383","article-title":"Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan","volume":"7","author":"Hsueh","year":"2001","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.xphs.2016.02.007_bib78","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.micinf.2003.08.009","article-title":"Antimicrobial resistance of Pseudomonas aeruginosa biofilms","volume":"5","author":"Drenkard","year":"2003","journal-title":"Microbes Infect"},{"key":"10.1016\/j.xphs.2016.02.007_bib79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature02122","article-title":"A\u00a0genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance","volume":"426","author":"Mah","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2016.02.007_bib80","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/jac\/dku151","article-title":"Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in\u00a0vitro dynamic biofilm model","volume":"69","author":"Lora-Tamayo","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.xphs.2016.02.007_bib81","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/656788","article-title":"Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa","volume":"202","author":"Herrmann","year":"2010","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3947\/ic.2015.47.1.27","article-title":"In\u00a0vitro comparison of anti-biofilm effects against carbapenem-resistant Acinetobacter baumannii: imipenem, colistin, tigecycline, rifampicin and combinations","volume":"47","author":"Song","year":"2015","journal-title":"Infect Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.007_bib83","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/JB.97.1.448-452.1969","article-title":"Electron microscopic studies on mode of action of polymyxin","volume":"97","author":"Koike","year":"1969","journal-title":"J\u00a0Bacteriol"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.007_bib84","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916003622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916003622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T16:48:03Z","timestamp":1600361283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916003622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0022354916003622"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.02.007","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}